Financials

  • Market Capitalization 218.69 M
  • Employee 92
  • Founded 2015
  • CEO N/A
  • Website www.kerostx.com
  • Headquarter Massachusetts, United States
  • FIGI BBG00H1HP9G9
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
8.85
Price to sales ratio
3.16

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
3535
GLSI
Greenwich LifeSciences, Inc. - Common stock
15.67 USD-16.34%-5.83%+20.82%+35.09%230.01 M USD
3545
TARA
Protara Therapeutics, Inc. - Common Stock
3.82 USD-4.26%+1.60%+0.53%+22.04%225.74 M USD
3570
VYGR
Voyager Therapeutics, Inc. - Common Stock
3.54 USD+2.31%+4.42%+17.22%-23.87%218.13 M USD
3571
CHRS
Coherus Oncology, Inc. - Common Stock
1.41 USD-3.42%+0.71%-0.70%-12.42%217.85 M USD

Frequently asked questions about Keros Therapeutics, Inc. Common Stock

What is the Keros Therapeutics, Inc. Common Stock stock price today?

The current price of Keros Therapeutics, Inc. Common Stock (KROS) is 11.03. Over the past 24 hours, the stock has changed by -1.78%. Follow the KROS chart for real-time price dynamics.

What is the stock ticker of Keros Therapeutics, Inc. Common Stock?

Keros Therapeutics, Inc. Common Stock trades under the ticker KROS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Keros Therapeutics, Inc. Common Stock stock going up?

KROS has changed by -0.81% over the last week, +11.19% over the last month, and -26.95% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Keros Therapeutics, Inc. Common Stock?

Keros Therapeutics, Inc. Common Stock currently has a market capitalization of 218.69 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Keros Therapeutics, Inc. Common Stock earnings last quarter?

Last quarter, Keros Therapeutics, Inc. Common Stock reported earnings of -1.45 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Keros Therapeutics, Inc. Common Stock revenue for the last quarter?

Keros Therapeutics, Inc. Common Stock reported quarterly revenue of 0. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Keros Therapeutics, Inc. Common Stock net income for the last quarter?

Keros Therapeutics, Inc. Common Stock reported net income of -28.71 M for the last quarter. The previous quarter showed -23.71 M, which means net income changed by -21.10%.

How many employees does Keros Therapeutics, Inc. Common Stock have?

As of the latest available data, Keros Therapeutics, Inc. Common Stock has 92 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Keros Therapeutics, Inc. Common Stock stock?

You can buy Keros Therapeutics, Inc. Common Stock (KROS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Keros Therapeutics, Inc. Common Stock stock?

Investing in Keros Therapeutics, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the KROS chart and related analysis on metatrader.com as part of your research.

News